Hikma launches Palonosetron Hydrochloride Injection

Product

Hikma launches Palonosetron Hydrochloride Injection

London, 29 March 2018 – Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody’s / BB+ S&P, both stable), announces that its wholly owned US subsidiary West-Ward Pharmaceuticals Corp. (West-Ward), has launched Palonosetron Hydrochloride (HCl) Injection, 0.25mg/2mL.

West-Ward’s Palonosetron HCI Injection is a serotonin-3 (5-HT3) receptor antagonist indicated in adults for:

  • Moderately emetogenic cancer chemotherapy – prevention of acute and delayed nausea and vomiting associated with initial and repeat courses
  • Highly emetogenic cancer chemotherapy – prevention of acute nausea and vomiting associated with initial and repeat courses

 

According to IQVIA, US sales of Palonosetron HCI Injection were approximately $447 million in the 12 months ending January 2018.

 

Riad Mechlaoui, Chief Executive Officer, Injectables Division, said, “We are very pleased to add Palonosetron HCI Injection to our oncology portfolio. The launch of this product further expands our broad Injectables portfolio, bringing value to our customers and patients in the US hospital setting, as well as driving long-term, sustainable growth for our business.”